Hepatitis C Virus

Ribozyme Technology Targets Antiviral Treatment And Detection

Published in Hepatitis Weekly, December 10th, 2001

Ribozyme Pharmaceuticals, Inc., (RPI) announced that five papers were presented in the areas of hepatitis C and hepatitis B diagnosis and treatment at the AASLD (American Association for the Study of Liver Diseases) annual meeting.

These papers highlight the continuing progress of the ribozyme technology platform for antiviral treatment and detection. AASLD's annual meeting was held in Dallas, Texas, November 9-13, 2001. The AASLD defines the leading edge in the study and treatment of liver and biliary diseases and its Annual Meeting is a once-a-year event with attendees from around the world.

In its initial presentation, RPI summarized the results...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry